Newsom committed California to making its own insulin. It’s at least a year behind his schedule
Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is ...
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
Balanced Outlook with Long-Term Optimism: Steve Scala Maintains Buy Rating for Eli Lilly & Co
TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why
Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...
중앙일보1h
Hanmi seeks to gain on Wegovy with its own weight-loss drug
Weight-loss drug Wegovy to begin sales in Korea after 16-month wait Novo Nordisk Pharma debuts smart sensor for insulin pens Son of Hanmi founder ousts mother as co-CEO as family feud continues 'I can ...